An Exploratory Evaluation of the Evolution of the Tumor Immune Microenvironment in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases Treated With Atezolizumab and Bevacizumab (INTEGRATE)
Latest Information Update: 23 Jul 2024
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary)
- Indications Liver cancer; Liver metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms INTEGRATE
- 17 Jul 2024 Planned End Date changed from 5 Dec 2024 to 31 Jul 2025.
- 13 Sep 2022 Trial design presented at the 47th European Society for Medical Oncology Congress
- 05 Jul 2021 Status changed from not yet recruiting to recruiting.